Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus DOS neoadjuvant study in locally advanced gastric cancer
ChiCTR1900020581Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib, docetaxel, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: R0 resection rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
Rivoceranibdocetaxeloxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900020581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020581.